RSV Hits Infants Hard as Vaccines Target 14,000 Hospitalizations

Karmactive Staff

Photo Source: NIAID (CC BY 2.0)

Rising cases of respiratory syncytial virus (RSV) across North America have prompted health authorities to accelerate the deployment of new preventive measures.

According to Health Canada, RSV cases are climbing rapidly, with infants under one year constituting the largest proportion of infections.

Photo Source: Realt0n12 (CC BY-SA 4.0)

Photo Source: Xavier Donat (CC BY-NC-ND 2.5)

According to CDC, Georgia ranks among the U.S. states with the highest weekly rates of positive RSV tests as of 12th December 2024.

Vaccinations such as Nirsevimab and Abrysvo, the maternal vaccine, have been developed to prevent RSV in the two groups- infants and the elderly.

Photo Source: CDC Global (CC BY 2.0)

Photo Source: MTSOFan (CC BY-NC-SA 2.0)

The aim of the vaccinations is to reduce rates of hospitalisations, deaths, outpatient visits, and emergency department visits due to RSV.

Region-wise, steps are being taken to prevent RSV, for instance, Quebec establishing a provincially-funded program for Nirsevimab to ensure vaccination for all.

Photo Source: Asian Development Bank (CC BY-NC 2.0)

Photo Source: Andrea Piacquadio (Pexels)

People infected with RSV show several symptoms such as congestion, runny nose, decreased appetite, coughing, sneezing, fever, wheezing, etc.

To prevent RSV, measures such as regular handwashing, surface sanitisation, avoiding contact with infected individuals, etc. can be taken.

Photo Source: Kaboompics.com (Pexels)